[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022

Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approvals forXofluza (influenza in children)Launch of a digital PCR diagnostic platform and of COVID-19, skin and breast cancer tests“Breakthrough Device Designation” granted for Alzheimer’s blood testsOutlook for 2022 confirmedSeverin Schwan, CEO of Roche: “Group sales grew 2% despite the expected sharp decline in COVID-19-related products in both divisions in the third quarter. The demand for our newer medicines for multiple sclerosis, haemophilia, spinal muscular atrophy and cancer remains high. I am particularly pleased that so many patients with severe eye disease have already accessed our new medicine Vabysmo and started treatment. Likewise, our Diagnostics Division base business continued to grow strongly. Based on our current assessment, we confirm the outlook for the full year.”SalesCHF millionsAs % of sales% change January –September 202220222...

Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news